Under construction – not a live service
Sign in
Taking peopleNo phase

Landscape of Gout in French Polynesia.

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07343336, who can take part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Lille Catholic University
Trial code
NCT07343336
Record updated
15 January 2026
Original description
The aim of this research is to characterise the genetic and molecular landscape of gout, inflammation and metabolic diseases, as well as the associated molecular, anthropomorphic and pathological characteristics.Read full original descriptionShow less

FENUA-METABOGOUT : Genetic Landscape of Gout, Inflammation and Metabolic Diseases in French Polynesia.

The aim of this research is to characterise the genetic and molecular landscape of gout, inflammation and metabolic diseases, as well as the associated molecular, anthropomorphic and pathological characteristics.

Inclusion: All participants:; Age between 18 and 75 years old inclusive; Signature of informed consent; Fasting for the collection of biological samples; Declared Polynesian ancestry; Affiliated to a social security scheme; General population group :; Not having participated to the 2021 TOPATA study; Visiting a general practitioner (for whatever reason); Gout Group :; Managed at the rheumatology clinic of the Taaone Hospital Centre (CHT) in Papeete by Dr Baptiste Gérard; Tophaceous gout sub-group:; Present with tophaceous gout; Gout crisis subgroup:; Be within 48 hours of the onset of a gout attack; Agree to return 1 week after inclusion for the second blood and urine sample; 2021 follow-up group:; To have been included in the TOPATA study in 2021; Have taken the genetic and biological samples that generated the genetic and serum urate data for the 2021 study; Have hyperuricaemia without signs of gout OR without hyperuricaemia or gout at the time of inclusion in TOPATA.

Exclusion: People suffering from other inflammatory rheumatic diseases; All participants :; Refusal or inability to understand or give consent; Physical inability to follow and respect the protocol; 1st degree relative*,; Person under guardianship or trusteeship; Pregnant or breast-feeding woman; If several relatives from the same household are eligible to participate, only one person may be included in the study. The choice is left to the discretion of the investigator or the first person met. However, both members of a couple (e.g. husband and wife) may participate; General population group :; Unable to return for sampling if required; Gout group :; Person wearing a knee prosthesis.

ClinicalTrials.gov NCT07343336